Pentixapharm Reports Third Quarter and Nine Months 2026 Results and Confirms Revised Outlook
Pentixapharm Holding AG reported its financial results for the third quarter and nine months of 2026 and confirmed its revised full-year net loss guidance of approximately €13 million, down from the previously expected €21.6 million. The company noted that the revision is driven by cost reductions, deferrals, and amortization changes, including a shift of approximately €3 million in PANDA study expenses into 2027. Following a €20.4 million capital raise during the quarter, the company expects its financial resources to support operations into 2028. Additionally, the company disclosed that BaFin concluded a review of its 2024 consolidated financial statements, identifying errors related to the overstatement of intangible assets and capital reserves.